DK0531548T3 - Carbostyril-forbindelser som anti-thrombotiske midler - Google Patents

Carbostyril-forbindelser som anti-thrombotiske midler

Info

Publication number
DK0531548T3
DK0531548T3 DK92907618.0T DK92907618T DK0531548T3 DK 0531548 T3 DK0531548 T3 DK 0531548T3 DK 92907618 T DK92907618 T DK 92907618T DK 0531548 T3 DK0531548 T3 DK 0531548T3
Authority
DK
Denmark
Prior art keywords
thrombotic agents
carbostyril compounds
carbostyril
compounds
thrombotic
Prior art date
Application number
DK92907618.0T
Other languages
Danish (da)
English (en)
Inventor
Takafumi Fujioka
Shuji Teramoto
Michiaki Tominaga
Yoichi Yabuuchi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of DK0531548T3 publication Critical patent/DK0531548T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
DK92907618.0T 1991-04-03 1992-03-26 Carbostyril-forbindelser som anti-thrombotiske midler DK0531548T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7022391 1991-04-03
JP2113792 1992-02-06

Publications (1)

Publication Number Publication Date
DK0531548T3 true DK0531548T3 (da) 1995-11-27

Family

ID=26358162

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92907618.0T DK0531548T3 (da) 1991-04-03 1992-03-26 Carbostyril-forbindelser som anti-thrombotiske midler

Country Status (8)

Country Link
US (2) US5401754A (ja)
EP (2) EP0647447B1 (ja)
JP (1) JPH05279256A (ja)
KR (1) KR930700106A (ja)
DE (2) DE69205106T2 (ja)
DK (1) DK0531548T3 (ja)
TW (1) TW201305B (ja)
WO (1) WO1992017178A1 (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464833A (en) * 1992-08-19 1995-11-07 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulating composition
US5654317A (en) * 1992-09-18 1997-08-05 Otsuka Pharmaceutical Company, Limited Antiarrhythmic agent
US5886010A (en) * 1995-01-09 1999-03-23 Otsuka Pharmaceutical Company, Limited TNF-αinhibitor
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US5902827A (en) * 1998-04-17 1999-05-11 Cell Pathways Method for treating patients with psoriasis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols
US5958982A (en) * 1998-04-17 1999-09-28 Cell Pathways, Inc. Method for treating patients with sarcoidosis by administering substituted sulfonyl indenyl acetic acids, esters and alcohols
US6025394A (en) * 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6660864B2 (en) 2001-06-29 2003-12-09 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6388080B1 (en) 2001-06-29 2002-05-14 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6573382B2 (en) 2001-06-29 2003-06-03 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6531603B1 (en) 2001-06-29 2003-03-11 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6596871B2 (en) 2001-06-29 2003-07-22 Grayson Walker Stowell Polymorphic forms of 6-[4-(1-cyclohexyl-1h-tetraol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
US6657061B2 (en) 2001-06-29 2003-12-02 Grayson Walker Stowell Polymorphic forms of 6-[4-1(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
EP1510216B8 (en) * 2002-06-05 2012-05-09 Komura, Toshio Antithrombogenic ceramic composition and article containing the same
EP1575923A2 (en) * 2002-12-23 2005-09-21 Artesian Therapeutics, Inc. CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST &bgr;-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE
CA2532807A1 (en) * 2003-07-17 2005-02-03 Cotherix, Inc. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
US20060089374A1 (en) * 2003-07-17 2006-04-27 Glenn Cornett Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
WO2005018563A2 (en) * 2003-08-22 2005-03-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
CA2537180A1 (en) * 2003-08-29 2005-03-10 Cotherix, Inc. Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
US20060154959A1 (en) * 2005-01-13 2006-07-13 Navitas Pharma Combination therapies of cicletanine and carvedilol
US20070141174A1 (en) * 2005-01-13 2007-06-21 Navitas Pharma, Inc. Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US20070105817A1 (en) * 2005-11-09 2007-05-10 Jim Page Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
CA2674367A1 (en) * 2007-01-03 2008-07-17 Glenn V. Cornett Cicletanine and pkc inhibitors in the treatment of pulmonary and cardiac disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4951271A (ja) * 1972-09-28 1974-05-18
JPS5082218A (ja) * 1973-11-10 1975-07-03
JPS5310989B2 (ja) * 1974-04-25 1978-04-18
JPS5936617B2 (ja) * 1976-03-05 1984-09-05 大塚製薬株式会社 カルボスチリル誘導体
JPS6059912B2 (ja) * 1978-02-28 1985-12-27 大塚製薬株式会社 カルボスチリル誘導体
IE46852B1 (en) * 1977-06-10 1983-10-05 Otsuka Pharma Co Ltd Novel carbostyril derivatives
JPS5430184A (en) * 1977-08-10 1979-03-06 Otsuka Pharmaceut Co Ltd 3,4-dihydrocarbostyril derivative
JPS5535019A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
ES8102679A1 (es) * 1979-01-30 1981-02-16 Otsuka Pharma Co Ltd Metodo de analizar fluidos corporales.
JPS55129268A (en) * 1979-03-28 1980-10-06 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5646812A (en) * 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS568319A (en) * 1980-03-26 1981-01-28 Otsuka Pharmaceut Co Ltd Antihistamine
JPS572274A (en) * 1980-06-06 1982-01-07 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5714574A (en) * 1980-06-27 1982-01-25 Otsuka Pharmaceut Co Ltd Carbostyril derivative
JPS5780322A (en) * 1980-11-05 1982-05-19 Otsuka Pharmaceut Co Ltd Cardiotonic agent
JPS5793962A (en) * 1980-12-01 1982-06-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
US5053514A (en) * 1988-08-10 1991-10-01 Otsuka Pharmaceutical Company, Limited Cardiotonics

Also Published As

Publication number Publication date
US5401754A (en) 1995-03-28
WO1992017178A1 (en) 1992-10-15
EP0531548B1 (en) 1995-09-27
EP0531548A1 (en) 1993-03-17
DE69205106T2 (de) 1996-02-29
EP0531548A4 (en) 1993-12-08
US5532253A (en) 1996-07-02
DE69233356D1 (de) 2004-07-01
EP0647447B1 (en) 2004-05-26
JPH05279256A (ja) 1993-10-26
KR930700106A (ko) 1993-03-13
DE69205106D1 (de) 1995-11-02
TW201305B (ja) 1993-03-01
EP0647447A1 (en) 1995-04-12

Similar Documents

Publication Publication Date Title
DK0531548T3 (da) Carbostyril-forbindelser som anti-thrombotiske midler
DK1028961T3 (da) Pleuromutilinderivater som antimikrobielle midler
DE10199002I2 (de) Substituierte thiazolidindion derivate
FI944804A0 (fi) Pyrimidinyyliasetamideja elastaasin estäjinä
FI943876A0 (fi) Heterobisykliset yhdisteet
DE69321461D1 (de) Desinfizierende zusammensetzung
DK0516349T3 (da) 2-hydroxy-2-phenylethylamin-derivater som beta-3-adrenoceptoragonister
BR1101108A (pt) Composto
FI103751B1 (fi) Mikrobien vastaisia koostumuksia
NO924000L (no) Antimikrobielle kinolontiourea-forbindelser
DK0693478T3 (da) Quinolinforbindelser
DK0606248T3 (da) Heteroarylaminer som hidtil ukendte acetylcholinesteraseinhibitorer
DK0869949T3 (da) Benzoxaziner som antimikrobielle midler
FI951009A0 (fi) Muskariinin vastaisina aineina käyttökelpoisia diaryylipiperatsinoasetamidiyhdisteitä
DE69300694D1 (de) Desinfizierende Zusammensetzungen.
FI940469A (fi) Kinoliinijohdannaisia immunostimulantteina
DK0975623T3 (da) Indazolamidforbindelser som sertoninerge midler
NO991384D0 (no) Substituerte heterocykler som anti-tumormidler
KR950700911A (ko) 살균약제로서의 치환된 3-피롤리디닐티오-카르바페넴(Substituted 3-Pyrrolidinylthio-Carbapenems as Antimicrobial Agents)
FI952049A (fi) Antimikrobiset 5-hydratsino-kinolonijohdannaiset
DK72693D0 (da) Compounds
DK124393D0 (da) Compounds
FI944825A0 (fi) Fenyylibentsoamidipohjaiset fungsidiyhdisteet
DK0660715T3 (da) Carbostyrilderivater som antiarytmiske midler
KR950700297A (ko) 5-HT3-수용체 길항제로서의 2,6-메타노-2H-퀴놀리진 유도체(2,6-Methano-2H-quinolizin derivative as 5-HT3-receptor antagonist)